University of Maryland Greenebaum Comprehensive Cancer Center Offers Novel Next-Generation CAR T-cell Therapy for B-cell Lymphomas in First-in-Human Clinical Trial
November 25, 2024Researchers at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) are conducting a first-in-human clinical trial of a novel next-generation CAR T-cell therapy to treat patients with recurrent or difficult-to-treat B-cell lymphomas, which are cancers of the lymphatic system.